• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重复给予骨髓来源的细胞可预防实验性矽肺的疾病进展。

Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis.

作者信息

Lopes-Pacheco Miquéias, Xisto Debora G, Ornellas Felipe M, Antunes Mariana A, Abreu Soraia C, Rocco Patricia R M, Takiya Christina M, Morales Marcelo M

机构信息

Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Brazil.

出版信息

Cell Physiol Biochem. 2013;32(6):1681-94. doi: 10.1159/000356603. Epub 2013 Dec 13.

DOI:10.1159/000356603
PMID:24356399
Abstract

BACKGROUND/AIMS: Bone marrow-derived cells (BMDCs) reduced mechanical and histologic changes in the lung in a murine model of silicosis, but these beneficial effects did not persist in the course of lung injury. We hypothesized that repeated administration of BMDCs may decrease lung inflammation and remodeling thus preventing disease progression.

METHODS

One hundred and two C57BL/6 mice were randomly divided into SIL (silica, 20 mg intratracheally [IT]) and control (C) groups (saline, IT). C and SIL groups were further randomized to receive BMDCs (2×10(6) cells) or saline IT 15 and 30 days after the start of the protocol.

RESULTS

By day 60, BMDCs had decreased the fractional area of granuloma and the number of polymorphonuclear cells, macrophages (total and M1 phenotype), apoptotic cells, the level of transforming growth factor (TGF)-β' and types I and III collagen fiber content in the granuloma. In the alveolar septa, BMDCs reduced the amount of collagen and elastic fibers, TGF-β, and the number of M1 and apoptotic cells. Furthermore, interleukin (IL)-1β, IL-1R1, caspase-3 mRNA levels decreased and the level of IL-1RN mRNA increased. Lung mechanics improved after BMDC therapy. The presence of male donor cells in lung tissue was not observed using detection of Y chromosome DNA.

CONCLUSION

repeated administration of BMDCs reduced inflammation, fibrogenesis, and elastogenesis, thus improving lung mechanics through the release of paracrine factors.

摘要

背景/目的:在矽肺小鼠模型中,骨髓来源的细胞(BMDCs)可减轻肺部的机械性和组织学变化,但这些有益作用在肺损伤过程中并未持续存在。我们推测,重复给予BMDCs可能会减轻肺部炎症和重塑,从而预防疾病进展。

方法

102只C57BL/6小鼠被随机分为矽肺组(二氧化硅,经气管内[IT]注入20mg)和对照组(C组,生理盐水,IT注入)。C组和矽肺组在实验开始后15天和30天进一步随机分为接受BMDCs(2×10⁶个细胞)或生理盐水IT注入组。

结果

到第60天时,BMDCs减少了肉芽肿的面积分数、多形核细胞、巨噬细胞(总数和M1表型)、凋亡细胞的数量,降低了转化生长因子(TGF)-β'水平以及肉芽肿中I型和III型胶原纤维含量。在肺泡间隔中,BMDCs减少了胶原和弹性纤维的数量、TGF-β以及M1和凋亡细胞的数量。此外,白细胞介素(IL)-1β、IL-1R1、半胱天冬酶-3 mRNA水平降低,而IL-1RN mRNA水平升高。BMDC治疗后肺力学得到改善。通过检测Y染色体DNA未观察到肺组织中有雄性供体细胞。

结论

重复给予BMDCs可减轻炎症、纤维生成和弹性生成,从而通过旁分泌因子的释放改善肺力学。

相似文献

1
Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis.重复给予骨髓来源的细胞可预防实验性矽肺的疾病进展。
Cell Physiol Biochem. 2013;32(6):1681-94. doi: 10.1159/000356603. Epub 2013 Dec 13.
2
Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis.骨髓源单核细胞治疗可减轻二氧化硅诱导的肺纤维化。
Eur Respir J. 2011 May;37(5):1217-25. doi: 10.1183/09031936.00205009. Epub 2010 Aug 6.
3
Intratracheal instillation of bone marrow-derived cell in an experimental model of silicosis.实验性矽肺模型中骨髓源性细胞的气管内滴注。
Respir Physiol Neurobiol. 2009 Dec 31;169(3):227-33. doi: 10.1016/j.resp.2009.09.004. Epub 2009 Sep 15.
4
Therapeutic effects of bone marrow-derived mononuclear cells from healthy or silicotic donors on recipient silicosis mice.健康或矽肺供者骨髓来源的单核细胞对受者矽肺小鼠的治疗作用。
Stem Cell Res Ther. 2017 Nov 10;8(1):259. doi: 10.1186/s13287-017-0699-7.
5
Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis.达沙替尼可减轻急性实验性矽肺中的肺部炎症和纤维化。
PLoS One. 2016 Jan 20;11(1):e0147005. doi: 10.1371/journal.pone.0147005. eCollection 2016.
6
Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.博舒替尼治疗可改善实验性矽肺中的肺部炎症和纤维化。
Front Physiol. 2017 Mar 15;8:159. doi: 10.3389/fphys.2017.00159. eCollection 2017.
7
Bone marrow-derived mononuclear cell therapy in experimental pulmonary and extrapulmonary acute lung injury.骨髓源单核细胞治疗实验性肺及肺外急性肺损伤。
Crit Care Med. 2010 Aug;38(8):1733-41. doi: 10.1097/CCM.0b013e3181e796d2.
8
Infusion of bone marrow mononuclear cells reduces lung fibrosis but not inflammation in the late stages of murine silicosis.输注骨髓单个核细胞可减轻小鼠矽肺晚期的肺纤维化,但不能减轻炎症。
PLoS One. 2014 Oct 9;9(10):e109982. doi: 10.1371/journal.pone.0109982. eCollection 2014.
9
Upregulated miR-29c suppresses silica-induced lung fibrosis through the Wnt/β-catenin pathway in mice.上调的miR-29c通过Wnt/β-连环蛋白通路抑制小鼠二氧化硅诱导的肺纤维化。
Hum Exp Toxicol. 2018 Sep;37(9):944-952. doi: 10.1177/0960327117741750. Epub 2017 Dec 8.
10
Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis.脂肪组织来源的间充质基质细胞及其细胞外囊泡在实验性矽肺中的治疗作用。
Respir Res. 2018 May 29;19(1):104. doi: 10.1186/s12931-018-0802-3.

引用本文的文献

1
Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases.增强间充质基质细胞治疗呼吸系统疾病治疗特性的功能增强策略。
Front Pharmacol. 2023 Mar 16;14:1067422. doi: 10.3389/fphar.2023.1067422. eCollection 2023.
2
Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives.间充质基质细胞衍生的细胞外囊泡在肺部疾病中的研究现状与展望
Front Cell Dev Biol. 2021 Feb 15;9:600711. doi: 10.3389/fcell.2021.600711. eCollection 2021.
3
Magnetic targeting increases mesenchymal stromal cell retention in lungs and enhances beneficial effects on pulmonary damage in experimental silicosis.
磁靶向增加间充质基质细胞在肺部的保留,并增强对实验性矽肺肺损伤的有益作用。
Stem Cells Transl Med. 2020 Oct;9(10):1244-1256. doi: 10.1002/sctm.20-0004. Epub 2020 Jun 15.
4
Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma.三例重症哮喘患者应用自体骨髓来源的单个核细胞治疗。
Stem Cell Res Ther. 2020 May 1;11(1):167. doi: 10.1186/s13287-020-01675-x.
5
Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma.多次脂肪组织来源的间充质基质细胞治疗可诱导实验性哮喘的免疫抑制。
Stem Cells Transl Med. 2020 Feb;9(2):250-260. doi: 10.1002/sctm.19-0120. Epub 2019 Nov 20.
6
Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome.间充质干细胞在急性呼吸窘迫综合征中的治疗益处的当前认识。
Cell Biol Toxicol. 2020 Feb;36(1):83-102. doi: 10.1007/s10565-019-09493-5. Epub 2019 Sep 4.
7
Current understanding of the immunosuppressive properties of mesenchymal stromal cells.当前对间充质基质细胞免疫抑制特性的认识。
J Mol Med (Berl). 2019 May;97(5):605-618. doi: 10.1007/s00109-019-01776-y. Epub 2019 Mar 22.
8
Impact of one versus two doses of mesenchymal stromal cells on lung and cardiovascular repair in experimental emphysema.单次与双次间充质干细胞治疗对实验性肺气肿肺及心血管修复的影响。
Stem Cell Res Ther. 2018 Nov 8;9(1):296. doi: 10.1186/s13287-018-1043-6.
9
Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases.间充质干细胞来源的细胞外囊泡疗法在炎症性肺病中的临床应用
J Clin Med. 2018 Oct 14;7(10):355. doi: 10.3390/jcm7100355.
10
Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma.二十碳五烯酸增强间充质基质细胞疗法在实验性变应性哮喘中的作用。
Front Immunol. 2018 May 24;9:1147. doi: 10.3389/fimmu.2018.01147. eCollection 2018.